Denmark's Evaxion Q2 net loss narrows on lower expenses

Evaxion expects to present three-year clinical data for EVX-01 in October 2026. The company also plans to submit a regulatory filing for EVX-04 clinical testing before the end of 2026.

Evaxion said its cash runway is sufficient to fund operations into the second half of 2027.

• Lower financial expenses — the company said a reduced derivative liability and related remeasurement lowered net financial expense compared with last year.
• Lower capital market costs — Evaxion said reduced capital market transaction costs helped narrow the net loss.
• Higher R&D spending — research and development expenses rose slightly from last year as the company progressed its pipeline according to plan.

Denmark vaccine developer Evaxion said its second-quarter net loss narrowed from a year earlier on lower financial expenses.

The company reported no revenue for the quarter, in line with its clinical-stage operations. Cash at hand of is expected to fund operations into the second half of .